The Uromigos

The Uromigos podcast, hosted by Tom Powles, professor of genitourinary oncology at Barts Cancer Centre, and Brian Rini, Ingram Professor of Medicine at Vanderbilt-Ingram Cancer Center, aims to broadcast the latest developments in GU cancer. Each episode features fascinating discussions with leading experts from around the world and dives into the data and clinical news relevant to the care of GU oncology patients. In their “Legends of GU Oncology” series, the podcasting duo focus on the founders of the field.

Articles by The Uromigos

The UromigosThe Uromigos | May 20, 2024
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Listen Now
The UromigosThe Uromigos | May 20, 2024
Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer.
The UromigosThe Uromigos | May 4, 2024
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.
The UromigosThe Uromigos | April 30, 2024
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
The UromigosThe Uromigos | April 30, 2024
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
The UromigosThe Uromigos | April 30, 2024
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
The UromigosThe Uromigos | April 30, 2024
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
The UromigosThe Uromigos | April 30, 2024
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
The UromigosThe Uromigos | April 26, 2024
Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC.
The UromigosThe Uromigos | April 18, 2024
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
The UromigosThe Uromigos | April 8, 2024
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
The UromigosThe Uromigos | April 8, 2024
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
The UromigosThe Uromigos | April 4, 2024
Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC.
The UromigosThe Uromigos | March 29, 2024
Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders.
The UromigosThe Uromigos | April 18, 2024
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
The UromigosThe Uromigos | March 14, 2024
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
The UromigosThe Uromigos | March 8, 2024
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
The UromigosThe Uromigos | March 14, 2024
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
The UromigosThe Uromigos | February 26, 2024
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
The UromigosThe Uromigos | March 14, 2024
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.